-DOCSTART- -X- O
Human -X- _ O
papillomavirus -X- _ O
( -X- _ O
HPV -X- _ O
) -X- _ O
infections -X- _ O
are -X- _ O
particularly -X- _ O
problematic -X- _ O
for -X- _ O
HIV -X- _ O
+ -X- _ O
and -X- _ O
solid -X- _ O
organ -X- _ O
transplant -X- _ O
patients -X- _ O
with -X- _ O
compromised -X- _ O
CD4+ -X- _ O
T -X- _ O
cell-dependent -X- _ O
immunity -X- _ O
as -X- _ O
they -X- _ O
produce -X- _ O
more -X- _ O
severe -X- _ O
and -X- _ O
progressive -X- _ O
disease -X- _ O
compared -X- _ O
to -X- _ O
healthy -X- _ O
individuals. -X- _ O
There -X- _ O
are -X- _ O
no -X- _ O
specific -X- _ O
treatments -X- _ O
for -X- _ O
chronic -X- _ O
HPV -X- _ O
infection -X- _ O
, -X- _ O
resulting -X- _ O
in -X- _ O
an -X- _ O
urgent -X- _ O
unmet -X- _ O
need -X- _ O
for -X- _ O
a -X- _ O
modality -X- _ O
that -X- _ O
is -X- _ O
safe -X- _ O
and -X- _ O
effective -X- _ O
for -X- _ O
both -X- _ O
immunocompromised -X- _ O
and -X- _ O
otherwise -X- _ O
normal -X- _ O
patients -X- _ O
with -X- _ O
recalcitrant -X- _ O
disease. -X- _ O
DNA -X- _ B-Intervention
vaccination -X- _ I-Intervention
is -X- _ O
attractive -X- _ O
because -X- _ O
it -X- _ O
avoids -X- _ O
the -X- _ O
risks -X- _ O
of -X- _ O
administration -X- _ O
of -X- _ O
live -X- _ O
vectors -X- _ O
to -X- _ O
immunocompromised -X- _ O
patients -X- _ O
, -X- _ O
and -X- _ O
can -X- _ O
induce -X- _ O
potent -X- _ O
HPV-specific -X- _ O
cytotoxic -X- _ O
T -X- _ O
cell -X- _ O
responses. -X- _ O
We -X- _ O
have -X- _ O
developed -X- _ O
a -X- _ O
DNA -X- _ B-Intervention
vaccine -X- _ I-Intervention
( -X- _ I-Intervention
pNGVL4a-hCRTE6E7L2 -X- _ I-Intervention
) -X- _ I-Intervention
encoding -X- _ O
calreticulin -X- _ O
( -X- _ O
CRT -X- _ O
) -X- _ O
fused -X- _ O
to -X- _ O
E6 -X- _ O
, -X- _ O
E7 -X- _ O
and -X- _ O
L2 -X- _ O
proteins -X- _ O
of -X- _ O
HPV-16 -X- _ O
, -X- _ O
the -X- _ O
genotype -X- _ O
associated -X- _ O
with -X- _ O
approximately -X- _ O
90 -X- _ O
% -X- _ O
vaginal -X- _ O
, -X- _ O
vulvar -X- _ O
, -X- _ O
anal -X- _ O
, -X- _ O
penile -X- _ O
and -X- _ O
oropharyngeal -X- _ O
HPV-associated -X- _ O
cancers -X- _ O
and -X- _ O
the -X- _ O
majority -X- _ O
of -X- _ O
cervical -X- _ O
cancers. -X- _ O
Administration -X- _ O
of -X- _ O
the -X- _ O
DNA -X- _ B-Outcome
vaccine -X- _ I-Outcome
by -X- _ I-Outcome
intramuscular -X- _ I-Outcome
( -X- _ I-Outcome
IM -X- _ I-Outcome
) -X- _ I-Outcome
injection -X- _ I-Outcome
followed -X- _ I-Outcome
by -X- _ I-Outcome

electroporation -X- _ B-Outcome
induced -X- _ I-Outcome
significantly -X- _ I-Outcome
greater -X- _ I-Outcome
HPV-specific -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
IM -X- _ I-Outcome
injection -X- _ I-Outcome
alone -X- _ I-Outcome
or -X- _ I-Outcome
mixed -X- _ I-Outcome
with -X- _ I-Outcome
alum. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
pNGVL4a-hCRTE6E7L2 -X- _ B-Outcome
DNA -X- _ I-Outcome
vaccination -X- _ I-Outcome
via -X- _ I-Outcome
electroporation -X- _ I-Outcome
of -X- _ I-Outcome
mice -X- _ I-Outcome
carrying -X- _ I-Outcome
an -X- _ I-Outcome
intravaginal -X- _ I-Outcome
HPV-16 -X- _ I-Outcome
E6 -X- _ I-Outcome
/ -X- _ I-Outcome
E7-expressing -X- _ I-Outcome
syngeneic -X- _ I-Outcome
tumor -X- _ I-Outcome
demonstrated -X- _ I-Outcome
more -X- _ I-Outcome
potent -X- _ I-Outcome
therapeutic -X- _ I-Outcome
effects -X- _ I-Outcome
than -X- _ I-Outcome
IM -X- _ I-Outcome
vaccination -X- _ I-Outcome
alone. -X- _ I-Outcome
Of -X- _ O
note -X- _ O
, -X- _ O
administration -X- _ B-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
DNA -X- _ I-Outcome
vaccine -X- _ I-Outcome
by -X- _ I-Outcome
IM -X- _ I-Outcome
injection -X- _ I-Outcome
followed -X- _ I-Outcome
by -X- _ I-Outcome
electroporation -X- _ I-Outcome
elicited -X- _ I-Outcome
potent -X- _ I-Outcome
E6 -X- _ I-Outcome
and -X- _ I-Outcome
E7-specific -X- _ I-Outcome
CD8+ -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
responses -X- _ I-Outcome
and -X- _ I-Outcome
antitumor -X- _ I-Outcome
effects -X- _ I-Outcome
despite -X- _ I-Outcome
CD4+ -X- _ I-Outcome
T -X- _ I-Outcome
cell-depletion -X- _ I-Outcome
, -X- _ I-Outcome
although -X- _ I-Outcome
no -X- _ I-Outcome
antibody -X- _ I-Outcome
response -X- _ I-Outcome
was -X- _ I-Outcome
detected. -X- _ I-Outcome
While -X- _ I-Outcome
CD4+ -X- _ I-Outcome
T -X- _ I-Outcome
cell-depletion -X- _ I-Outcome
did -X- _ I-Outcome
reduce -X- _ I-Outcome
the -X- _ I-Outcome
E6 -X- _ I-Outcome
and -X- _ I-Outcome
E7-specific -X- _ I-Outcome
CD8+ -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
response -X- _ I-Outcome
, -X- _ I-Outcome
it -X- _ I-Outcome
remained -X- _ I-Outcome
sufficient -X- _ I-Outcome
to -X- _ I-Outcome
prevent -X- _ I-Outcome
subcutaneous -X- _ I-Outcome
tumor -X- _ I-Outcome
growth -X- _ I-Outcome
and -X- _ I-Outcome
to -X- _ I-Outcome
eliminate -X- _ I-Outcome
circulating -X- _ I-Outcome
tumor -X- _ I-Outcome
cells -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
model -X- _ I-Outcome
of -X- _ I-Outcome
metastatic -X- _ I-Outcome
HPV-16+ -X- _ I-Outcome
cancer. -X- _ I-Outcome
Thus -X- _ O
, -X- _ O
the -X- _ O
antibody -X- _ O
response -X- _ O
was -X- _ O
CD4-dependent -X- _ O
, -X- _ O
whereas -X- _ O
CD4+ -X- _ O
T -X- _ O
cell -X- _ O
help -X- _ O
enhanced -X- _ O
the -X- _ O
E6 -X- _ O
/ -X- _ O
E7-specific -X- _ O
CD8+ -X- _ O
T -X- _ O
cell -X- _ O
immunity -X- _ O
, -X- _ O
but -X- _ O
was -X- _ O
not -X- _ O
required. -X- _ O
Taken -X- _ O
together -X- _ O
, -X- _ O
our -X- _ O
data -X- _ O
suggest -X- _ O
that -X- _ O
pNGVL4a-hCRTE6E7L2 -X- _ B-Outcome
DNA -X- _ I-Outcome
vaccination -X- _ I-Outcome
via -X- _ I-Outcome
electroporation -X- _ I-Outcome
warrants -X- _ I-Outcome
testing -X- _ I-Outcome
in -X- _ I-Outcome
otherwise -X- _ I-Outcome
healthy -X- _ I-Outcome
patients -X- _ I-Outcome
and -X- _ I-Outcome
those -X- _ I-Outcome
with -X- _ I-Outcome
compromised -X- _ I-Outcome
CD4+ -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
immunity -X- _ I-Outcome
to -X- _ I-Outcome
treat -X- _ I-Outcome
HPV-16-associated -X- _ I-Outcome
anogenital -X- _ I-Outcome
disease -X- _ I-Outcome
and -X- _ I-Outcome
cancer -X- _ I-Outcome
. -X- _ O

